Humana entered into a new May 31, 2024 364-day unsecured revolving credit agreement for $2,107,812,500 that replaces 364-Day $1.5 billion facility, which expired under its terms, and the company said the agreement was entered into on June 2, 2023 364-day.

1. 01

   Humana entered into a new May 31, 2024 364-day unsecured revolving credit agreement for $2,107,812,500 that replaces 364-Day $1.5 billion facility, which expired under its terms, and the company said the agreement was entered into on June 2, 2023 364-day.

2. 02

   The company said it increased the commitments under its existing five-year unsecured revolving credit agreement from $2,500,000,000 to $2,642,187,500 through a first amendment.

3. 03

   The company said it will use borrowings under both revolving credit agreements for general corporate purposes, with loans bearing interest at Term SOFR or the base rate plus a spread, and that the agreements permit up to $500 million of incremental commitments.

4. 04

   The company said that as of May 31, 2024 it had no borrowings outstanding under its revolving credit agreements, with approximately $18.1 million of issued and undrawn letters of credit under the 5-Year agreement, and that remaining borrowing capacity was approximately $2.624 billion under the 5-Year agreement and approximately $2.11 billion under the 364-Day agreement.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.